Literature DB >> 33413293

Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis.

Sara C Auld1, Hardy Kornfeld2, Pholo Maenetje3, Mandla Mlotshwa3, William Chase4, Mboyo di-Tamba Vangu5, Drew A Torigian4, Robert S Wallis3, Gavin Churchyard3,6, Gregory P Bisson4,7.   

Abstract

BACKGROUND: While tuberculosis is considered a risk factor for chronic obstructive pulmonary disease, a restrictive pattern of pulmonary impairment may actually be more common among tuberculosis survivors. We aimed to determine the nature of pulmonary impairment before and after treatment among people with HIV and tuberculosis and identify risk factors for long-term impairment.
METHODS: In this prospective cohort study conducted in South Africa, we enrolled adults newly diagnosed with HIV and tuberculosis who were initiating antiretroviral therapy and tuberculosis treatment. We measured lung function and symptoms at baseline, 6, and 12 months. We compared participants with and without pulmonary impairment and constructed logistic regression models to identify characteristics associated with pulmonary impairment.
RESULTS: Among 134 participants with a median CD4 count of 110 cells/μl, 112 (83%) completed baseline spirometry at which time 32 (29%) had restriction, 13 (12%) had obstruction, and 9 (7%) had a mixed pattern. Lung function was dynamic over time and 30 (33%) participants had impaired lung function at 12 months. Baseline restriction was associated with greater symptoms and with long-term pulmonary impairment (adjusted odds ratio 5.44, 95% confidence interval 1.16-25.45), while baseline obstruction was not (adjusted odds ratio 1.95, 95% confidence interval 0.28-13.78).
CONCLUSIONS: In this cohort of people with HIV and tuberculosis, restriction was the most common, symptomatic, and persistent pattern of pulmonary impairment. These data can help to raise awareness among clinicians about the heterogeneity of post-tuberculosis pulmonary impairment, and highlight the need for further research into mediators of lung injury in this vulnerable population.

Entities:  

Keywords:  HIV; Pulmonary disease; Respiratory function tests; Tuberculosis

Mesh:

Substances:

Year:  2021        PMID: 33413293      PMCID: PMC7791797          DOI: 10.1186/s12890-020-01368-4

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.320


  38 in total

1.  Excess lung function decline in gold miners following pulmonary tuberculosis.

Authors:  J Ross; R I Ehrlich; E Hnizdo; N White; G J Churchyard
Journal:  Thorax       Date:  2010-09-25       Impact factor: 9.139

Review 2.  Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD.

Authors:  R N van Zyl Smit; M Pai; W W Yew; C C Leung; A Zumla; E D Bateman; K Dheda
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

3.  Causal diagrams for epidemiologic research.

Authors:  S Greenland; J Pearl; J M Robins
Journal:  Epidemiology       Date:  1999-01       Impact factor: 4.822

Review 4.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Authors:  Dave Singh; Alvar Agusti; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Gerard J Criner; Peter Frith; David M G Halpin; Meilan Han; M Victorina López Varela; Fernando Martinez; Maria Montes de Oca; Alberto Papi; Ian D Pavord; Nicolas Roche; Donald D Sin; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Claus Vogelmeier
Journal:  Eur Respir J       Date:  2019-05-18       Impact factor: 16.671

Review 5.  Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.

Authors:  Bridget F Collins; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2019-10-01

6.  Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up.

Authors:  D M Mannino; F Holguin; B I Pavlin; J M Ferdinands
Journal:  Int J Tuberc Lung Dis       Date:  2005-06       Impact factor: 2.373

7.  Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study.

Authors:  D M Mannino; A S Buist; T L Petty; P L Enright; S C Redd
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

8.  CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis.

Authors:  Zoe Daniil; Panagiota Kitsanta; George Kapotsis; Maria Mathioudaki; Androniki Kollintza; Marilena Karatza; Joseph Milic-Emili; Charis Roussos; Spyros A Papiris
Journal:  Respir Res       Date:  2005-07-24

9.  Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome.

Authors:  Sara C Auld; Pholo Maenetje; Shruthi Ravimohan; Drew Weissman; Itai Ncube; Mandla Mlotshwa; Nelly Ratsela; William Chase; Mboyo-Di-Tamba Vangu; Robert Wallis; Gavin Churchyard; Hardy Kornfeld; Gregory P Bisson
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

10.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.

Authors:  Graeme Meintjes; Stephen D Lawn; Fabio Scano; Gary Maartens; Martyn A French; William Worodria; Julian H Elliott; David Murdoch; Robert J Wilkinson; Catherine Seyler; Laurence John; Maarten Schim van der Loeff; Peter Reiss; Lut Lynen; Edward N Janoff; Charles Gilks; Robert Colebunders
Journal:  Lancet Infect Dis       Date:  2008-08       Impact factor: 25.071

View more
  3 in total

1.  World AIDS Day: 40 years of an evolving pulmonary landscape.

Authors:  Kristina Crothers; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-11-10       Impact factor: 5.464

2.  Clinical and Immunological Markers of Pulmonary Impairment Among People With HIV in India.

Authors:  Anurima Baidya; Shashikala Sangle; Ivan Marbaniang; Vandana Kulkarni; Prasad Deshpande; Smita Nimkar; Amol Chavan; Sonali Salvi; Rahul Lokhande; Dileep Kadam; Amita Gupta; Vidya Mave; Akshay N Gupte
Journal:  Open Forum Infect Dis       Date:  2022-05-11       Impact factor: 4.423

3.  Remodeling the matrix: doxycycline modulates tuberculosis immunopathology.

Authors:  Jason D Simmons; Thomas R Hawn
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.